HL Genomics officially began trading on the KOSDAQ market on the 24th after its listing.

As of 9:01 a.m. today, HL Genomics' stock is trading at 20,100 won, down 6.51% from its public offering price. Given the high volatility typical of newly listed stocks, market attention is focused on how trading will unfold throughout the session.

HL Genomics is a company engaged in pharmaceutical research and development as well as manufacturing, processing, storage, and distribution businesses, primarily producing active pharmaceutical ingredients (APIs) for prescription drugs.

The earlier public subscription for general investors recorded strong competition rates. KB Securities' proportional competition rate stood at 1,364.26 to 1, while IBK Investment Securities recorded 1,057.14 to 1. The number of equally allocated shares based on minimum subscription requirements was 1.56 shares at KB Securities and 1.43 shares at IBK Investment Securities.

Overall domestic market sentiment today is also expected to serve as a variable. With both the KOSPI and KOSDAQ having shown strength the previous day, today's market mood could influence HL Genomics' supply and demand dynamics.

Key points to watch on the first day of trading include intraday supply-demand shifts and the stock's direction relative to the public offering price. Due to the high volatility characteristic of newly listed stocks, near-term attention is concentrated on the price trend through the closing bell.

[This article is not intended to solicit investment. All final investment decisions and responsibilities rest with the investor.]